Journal of Urologic Oncology

Editorial

March 31, 2024

JUO, the Journal of Urologic Oncology, Celebrates Its Second Anniversary

Cheol Kwak

J Urol Oncol. 2024;22(1):1-3.

Invited Review

March 31, 2024

Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review

Chang Wook Jeong

J Urol Oncol. 2024;22(1):4-10.

Prostate cancer (PCa) is the second most common cancer globally. However, significant disparities in incidence and mortality exist between countries, especially between Western and Asian regions. This review discusses the...

Invited Review

March 31, 2024

Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review

Minseok Suh, Gi Jeong Cheon

J Urol Oncol. 2024;22(1):11-20.

In managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-specific membrane antigen (PSMA) theranostics marks a significant advancement, addressing the disease's spectrum from indolent forms to aggressive metastatic...

Original Article

March 31, 2024

High-Grade Late Urinary Toxicity Following Salvage Radiotherapy After Radical Prostatectomy: A Retrospective Cohort Study

Seung-Kwon Choi, Myong Kim, Sang Mi Lee, et al.

J Urol Oncol. 2024;22(1):21-28.

Purpose: To find out the incidence and predictors for late high-grade genitourinary (GU) toxicity following salvage radiotherapy (SRT), we investigated the consecutive patients who were treated with SRT after radical...

Original Article

March 31, 2024

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study

Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, et al.

J Urol Oncol. 2024;22(1):29-33.

Purpose: To assess the feasibility and short-term efficacy of maintenance enzalutamide following first-line docetaxel plus androgen deprivation therapy (ADT) in patients with high-volume, metastatic castration-naive prostate cancer (mCNPC). Materials and Methods:...

Systemic Review and Meta-analysis

March 31, 2024

Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.

J Urol Oncol. 2024;22(1):34-41.

Purpose: The aim of this study was to assess the effects of tyrosine kinase inhibitors (TKIs) following metastasectomy in patients with metastatic renal cell carcinoma (mRCC). Materials and Methods: A systematic...

Original Article

March 31, 2024

Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis

Jung Hoon Kim, Ji Woong Hwang

J Urol Oncol. 2024;22(1):42-51.

Purpose: Renal cell carcinoma (RCC) is a relatively common malignancy of the urinary tract. Over the past few decades, methodologies for diagnosing and managing patients with RCC have shown various...

Original Article

March 31, 2024

Prognostic Factors and Cancer-Specific Survival of Surgically Managed Renal Cell Carcinoma With Venous Thrombus: A 30-Year Experience at a Tertiary Referral Center

Hyun Young Lee, Yunjoong Kim, Bumjin Lim, et al.

J Urol Oncol. 2024;22(1):52-58.

Purpose: This study investigated the prognostic factors and cancer-specific survival (CSS) of patients who had renal cell carcinoma (RCC) with venous thrombus and underwent radical nephrectomy with thrombectomy (RNTx). Materials and...

Original Article

March 31, 2024

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al.

J Urol Oncol. 2024;22(1):59-67.

Purpose: TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study...

Invited Review

March 31, 2024

Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma

Sung Han Kim, Ilma S. Savul, Seth P. Lerner

J Urol Oncol. 2024;22(1):68-77.

Radical nephroureterectomy (RNU) remains the gold standard for the surgical management of upper tract urothelial carcinoma (UTUC) from the ureterovesical junction to the renal pelvis. However, the removal of the...

Systemic Review and Meta-analysis

March 31, 2024

Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients

Stefani Frost, Parisa Ziarati, Ryan Moen, et al.

J Urol Oncol. 2024;22(1):78-94.

Purpose: Diabetes mellitus, a frequent comorbid condition in cancer patients, has been shown to increase risk of all-site cancer mortality. This relationship has not been systematically studied in bladder cancer...

Erratum

March 31, 2024

Declaration of Conflict of Interest for Editorial Board Members’ Articles

J Urol Oncol. 2024;22(1):95-96.

JUO, the Journal of Urologic Oncology, Celebrates Its Second Anniversary Cheol Kwak J Urol Oncol. 2024;22(1):1-3. Editorial Mar 31, 2024 Full text PubReader ePub PDF	Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review Chang Wook Jeong J Urol Oncol. 2024;22(1):4-10. Cited By 1 Invited Review Mar 31, 2024 Prostate Cancer Full text PubReader ePub PDF
Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review Minseok Suh, Gi Jeong Cheon J Urol Oncol. 2024;22(1):11-20. Cited By 1 Invited Review Mar 31, 2024 Prostate Cancer Full text PubReader ePub PDF	High-Grade Late Urinary Toxicity Following Salvage Radiotherapy After Radical Prostatectomy: A Retrospective Cohort Study Seung-Kwon Choi, Myong Kim, Sang Mi Lee, et al. J Urol Oncol. 2024;22(1):21-28. Cited By 1 Original Article Mar 31, 2024 Prostate Cancer Full text PubReader ePub PDF
Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study Sung Hee Lim, Sung Wook Cho, Jae Hoon Chung, et al. J Urol Oncol. 2024;22(1):29-33. Cited By 1 Original Article Mar 31, 2024 Prostate Cancer Full text PubReader ePub PDF	Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al. J Urol Oncol. 2024;22(1):34-41. Cited By 1 Systemic Review and Meta-analysis Mar 31, 2024 Kidney Cancer Full text PubReader ePub PDF Supplementary Material
Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis Jung Hoon Kim, Ji Woong Hwang J Urol Oncol. 2024;22(1):42-51. Cited By 1 Original Article Mar 31, 2024 Kidney Cancer Full text PubReader ePub PDF	Prognostic Factors and Cancer-Specific Survival of Surgically Managed Renal Cell Carcinoma With Venous Thrombus: A 30-Year Experience at a Tertiary Referral Center Hyun Young Lee, Yunjoong Kim, Bumjin Lim, et al. J Urol Oncol. 2024;22(1):52-58. Cited By 1 Original Article Mar 31, 2024 Kidney Cancer Full text PubReader ePub PDF
Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al. J Urol Oncol. 2024;22(1):59-67. Cited By 1 Original Article Mar 31, 2024 Kidney Cancer Full text PubReader ePub PDF	Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma Sung Han Kim, Ilma S. Savul, Seth P. Lerner J Urol Oncol. 2024;22(1):68-77. Cited By 1 Invited Review Mar 31, 2024 Bladder Cancer Full text PubReader ePub PDF
Poorer Outcomes in Bladder Cancer Patients With Diabetes: A Systematic Review and Meta-analysis Addressing Over 226,472 Bladder Cancer Patients Stefani Frost, Parisa Ziarati, Ryan Moen, et al. J Urol Oncol. 2024;22(1):78-94. Cited By 1 Systemic Review and Meta-analysis Mar 31, 2024 Bladder Cancer Full text PubReader ePub PDF Supplementary Material	Declaration of Conflict of Interest for Editorial Board Members’ Articles J Urol Oncol. 2024;22(1):95-96. Corrects: J Urol Oncol 2023;21(1):5 Corrects: J Urol Oncol 2023;21(1):14 Corrects: J Urol Oncol 2023;21(1):23 Corrects: J Urol Oncol 2023;21(1):53 Corrects: J Urol Oncol 2023;21(1):59 Corrects: J Urol Oncol 2023;21(1):79 Corrects: J Urol Oncol 2023;21(2):140 Erratum Mar 31, 2024 Full text PubReader ePub PDF

4,027	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
3,701	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
3,070	The Present and Future of Intravesical Therapy in Bladder Cancer
2,843	Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
2,775	Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?

Cited By 4	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 2	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 2	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Cited By 2	Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma